Journal: Advanced Science

Article Title: Single‐Cell RNA Sequencing Identifies MMP11 + Cancer‐Associated Fibroblasts as Drivers of Angiogenesis and Bladder Cancer Progression

doi: 10.1002/advs.202502774

Figure Lengend Snippet: MMP11 + mCAFs drive the migration of ESM1 + tECs through the WNT5A‐MCAM signaling axis. A) Signaling output landscape of different cell populations, visualized to highlight key pathways and intercellular communication hubs. B) Communication intensity of the WNT5A‐MCAM signaling axis between MMP11 + mCAFs with distinct cell populations. C) UMAP plot displaying the classification of endothelial cell subpopulation. D) Expression levels of MCAM across identified endothelial subpopulations, visualized as a UMAP plot (top) and a Dot plot (bottom) overlay. E) GO enrichment analysis showing key biological processes and pathways associated with upregulated genes in ESM1 + tECs. F) Heatmap of pathway activity variations scored by GSVA for each cell between different endothelial groups. G) IF staining for spatial localization of MMP11 + mCAFs, confirming their proximity to endothelial regions of interest. Scale bar = 20 µm. The white arrow indicates the MMP11 + mCAF cells. H) Transwell migration assay demonstrating the effect of WNT5A and Box5‐TFA, with representative images showing cell migration trends. Scale bar = 50 µm, n = 3. I) Angiogenesis assays assessing effect of WNT5A and Box5‐TFA on tube formation activity in HUVECs. Scale bar = 50 µm, n = 3. J–L) Quantifications of migrated cells in Transwell migration assay (J), junction numbers (K), and mesh numbers (L) in Angiogenesis assays. Statistical analysis was performed using Student's t ‐test; ** p < 0.01, *** p < 0.001, **** p < 0.0001. M) Transcription factors specific to endothelial subpopulations, identified via single‐cell transcriptomics. N) ESM1 + tEC‐specific transcription factors and their regulatory target genes, mapped to demonstrate transcriptional control over ESM1 + tEC signature genes. O) Correlation between ESM1 + tEC‐specific transcription factors genes and MCAM expression, tested by Spearman correlation.

Article Snippet: HUVEC cells were treated with PBS, WNT5A (10 ng mL −1 ), WNT5A + Box5‐TFA (10 μ m ), or Box5‐TFA (10 μ m ) for 12 h. HBdSF fibroblast cells were treated with PBS, BMP2 (5 ng mL −1 ), LDN193189 (10 ug mL −1 , MedChemExpress, New Jersey, USA; HY‐12071), or BMP2 + LDN193189 for 12 h. Total RNA was extracted using TRIzol reagent (Invitrogen, 15596026CN) according to the manufacturer's instructions.

Techniques: Migration, Expressing, Activity Assay, Staining, Transwell Migration Assay, Single-cell Transcriptomics, Control

Journal: European Journal of Oral Sciences

Article Title: Higher expression of WNT 5A protein in oral squamous cell carcinoma compared with dysplasia and oral mucosa with a normal appearance

doi: 10.1111/eos.12352

Figure Lengend Snippet: Expression of WNT 5A in different tissue regions. (A and B) Nuclear expression of WNT5A in oral mucosa with normal appearance. (C and D) Cytoplasmic and nuclear expression of WNT5A in severe‐grade dysplasia (black arrows). (E and F) Cancer islands; black arrows indicate expression of WNT5A in the cytoplasm in the periphery of cancer islands and red arrows indicate the absence of expression of WNT5A in the central part of the cancer islands. Scale bar = 50 μ m.

Article Snippet: The cells were cultured in six‐well plates until 80% confluence was reached, rinsed with PBS, incubated with serum‐free medium overnight, rinsed again with PBS, and treated either with 0.1% BSA in PBS as the control or with 0.4 μ g/ml of recombinant WNT5A (rWNT5A; 645‐WN; R&D Systems, Minneapolis, MN, USA) in serum‐free medium.

Techniques: Expressing

Journal: European Journal of Oral Sciences

Article Title: Higher expression of WNT 5A protein in oral squamous cell carcinoma compared with dysplasia and oral mucosa with a normal appearance

doi: 10.1111/eos.12352

Figure Lengend Snippet: Effect of recombinant WNT 5A ( rWNT 5A) on expression of β ‐catenin and E‐cadherin in SCC 9 and SCC 25. (A, E) Representative western blots of expression of active β ‐catenin, total β ‐catenin, and E‐cadherin after stimulation with rWNT 5A. (B, F) Quantification of relative E‐cadherin; (C, G) quantification of active β ‐catenin; (D, H) quantification of total β ‐catenin. All quantifications were performed on four separate experiments.

Article Snippet: The cells were cultured in six‐well plates until 80% confluence was reached, rinsed with PBS, incubated with serum‐free medium overnight, rinsed again with PBS, and treated either with 0.1% BSA in PBS as the control or with 0.4 μ g/ml of recombinant WNT5A (rWNT5A; 645‐WN; R&D Systems, Minneapolis, MN, USA) in serum‐free medium.

Techniques: Recombinant, Expressing, Western Blot

Journal: European Journal of Oral Sciences

Article Title: Higher expression of WNT 5A protein in oral squamous cell carcinoma compared with dysplasia and oral mucosa with a normal appearance

doi: 10.1111/eos.12352

Figure Lengend Snippet: Expression of WNT5A, β ‐catenin, and E‐cadherin in oral mucosa with a normal appearance, dysplasia, and at the invasive front of oral squamous cell carcinoma (OSCC)

Article Snippet: The cells were cultured in six‐well plates until 80% confluence was reached, rinsed with PBS, incubated with serum‐free medium overnight, rinsed again with PBS, and treated either with 0.1% BSA in PBS as the control or with 0.4 μ g/ml of recombinant WNT5A (rWNT5A; 645‐WN; R&D Systems, Minneapolis, MN, USA) in serum‐free medium.

Techniques: Expressing, Staining

Journal: Oncotarget

Article Title: Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

doi: 10.18632/oncotarget.5643

Figure Lengend Snippet: Figure 6: Knockdown of WNT5A in serous ovarian cancer decreases migration and invasion. A. WNT5A is decreased at the mRNA level following siRNA (A) induced knockdown in serous ovarian cancer (OVCAR3) cells. No effect on ROR1 or ROR2 mRNA level. qRT-PCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, RPL13A). Results represent an average of three experiments. Error bars represent the s.d of the mean. **P < 0.01. B. Cell proliferation decreases following WNT5A knockdown in OVCAR3 cells over a 48–72 hour period, however did not come to significance (P = 0.076). Results represent the average of three independent experiments. Error bars represent the s.d of the mean. C. Relative cell migration performed using the transwell migration assay is significantly decreased following WNT5A knockdown in OVCAR3 cells. Results represent an average of three experiments. Error bars represent the s.d of the mean. **P < 0.01. D. Relative cell invasion performed using the matrigel pre coated transwell assay is significantly decreased following WNT5A knockdown in OVCAR3 cells. Results represent the average of three experiments. Error bars represent the s.d of the mean. **P < 0.01. E. Representative picture of OVCAR3 cells invading matrigel over 48 hours. F. Luciferase assay determined no change in β-catenin dependent signalling after WNT5A knockdown in OVCAR3. Relative β-catenin driven transcription activity was calculated as a TOP/FOP ratio in triplicate wells. Results represent an average of three experiments. Error bars represent the s.d of the mean.

Article Snippet: Triplicate wells were then stimulated with 40 ng/ul of Wnt3a (#5036-WN-010/CF R&D Systems, Minneapolis, USA) and Wnt5a (#645-WN-010, R&D Systems, Minneapolis, USA) alongside an un-stimulated control over night.

Techniques: Knockdown, Migration, Quantitative RT-PCR, Transwell Migration Assay, Transwell Assay, Luciferase, Activity Assay

Journal: Oncotarget

Article Title: Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

doi: 10.18632/oncotarget.5643

Figure Lengend Snippet: Figure 7: Simultaneous knockdown of WNT5A and ROR2 in serous ovarian cancer decreases proliferation, migration and invasion. A. WNT5A and ROR2 are decreased at the mRNA level following siRNA (A) induced knockdown in serous ovarian cancer (OVCAR3) cells. No effect on ROR1 mRNA level. qRT-PCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, RPL13A). Results represent an average of three experiments. Error bars represent the s.d of the mean. *P < 0.05, **P < 0.01. B. Cell proliferation decreases following WNT5A and ROR2 knockdown in OVCAR3 cells after 72 hours. Results represent the average of three independent experiments. Error bars represent the s.d of the mean. *P < 0.05. C. Relative cell migration performed using the transwell migration assay is significantly decreased following WNT5A and ROR2 knockdown in OVCAR3 cells. Results represent an average of three experiments. Error bars represent the s.d of the mean. *P < 0.05. D. Relative cell invasion performed using the matrigel pre coated transwell assay is significantly decreased following WNT5A and ROR2 knockdown in OVCAR3 cells. Results represent the average of three experiments. Error bars represent the s.d of the mean. ***P < 0.001. E. Representative picture of OVCAR3 cells invading matrigel over 48 hours. F. Luciferase assay determined a slight non-significant increase in WNT3A stimulated β-catenin dependent signalling after WNT5A and ROR2 knockdown in OVCAR3. Relative β-catenin driven transcription activity was calculated as a TOP/FOP ratio in triplicate wells. Results represent an average of three experiments. Error bars represent the s.d of the mean.

Article Snippet: Triplicate wells were then stimulated with 40 ng/ul of Wnt3a (#5036-WN-010/CF R&D Systems, Minneapolis, USA) and Wnt5a (#645-WN-010, R&D Systems, Minneapolis, USA) alongside an un-stimulated control over night.

Techniques: Knockdown, Migration, Quantitative RT-PCR, Transwell Migration Assay, Transwell Assay, Luciferase, Activity Assay

Journal: Disease models & mechanisms

Article Title: The Meckel-Gruber syndrome protein TMEM67 controls basal body positioning and epithelial branching morphogenesis in mice via the non-canonical Wnt pathway.

doi: 10.1242/dmm.019083

Figure Lengend Snippet: Fig. 5. The receptor tyrosine kinase-like orphan receptor ROR2 colocalises and interacts with TMEM67, and is dependent on this interaction for phosphorylation. (A) Four-colour IF imaging showing that endogenous ROR2 (green) colocalizes with TMEM67 (blue) and RPGRIP1L (red) at the ciliary transition zone. Arrowheads indicate regions shown in magnified insets. DAPI is pseudocoloured in grey. Scale bar: 10 μm. (B) Anti-HA co-immunoprecipitations (IPs) demonstrating interaction between full-length exogenous HA-tagged TMEM67 (size 115 kDa) and FLAG-tagged ROR2 (size 105 kDa). Input whole-cell extracts (WCE) for the indicated transfected constructs are on the left. IP of an irrelevant protein (HA-tagged MCPH1) was a negative control. Results are shown for immunoblotting (IB) for anti-FLAG (upper panel) and anti-TMEM67 (lower panel). * indicates a non-specific band in IPs; see supplementary material Fig. S6 for full unprocessed images. (C) Upper panel: IPs demonstrating interaction between FLAG-tagged ROR2 and endogenous TMEM67. Input WCE is shown on the left, and negative control IPs include a no antibody (Ab) control and goat (Gt) and rabbit (Rb) irrelevant (irr.) polyclonal antibodies (PAb). Immunoblotting (IB) for anti-FLAG shows pulldown of FLAG-ROR2 by Gt anti-ROR2 and Rb anti-TMEM67. Lower panel: IPs with irrelevant protein (FLAG-MCPH1, size 93 kDa). (E) Loss of the active phosphorylated ROR2 isoform (labelled P) in mutant Tmem67−/−cells following Wnt5a treatment, compared with strong induction of the active isoform (upper band, as indicated) in wild-type Tmem67+/+ cells. Loading control is for β-actin.

Article Snippet: Protein expression and in vitro binding assay Purified recombinant Wnt3a and Wnt5a proteins (R&D Systems Inc.) and purified BSA as a negative control (Sigma-Aldrich Co. Ltd), were labelled with NHS-fluorescein (Thermo Fisher Scientific Inc.), as described by the manufacturer.

Techniques: Phospho-proteomics, Imaging, Transfection, Construct, Negative Control, Western Blot, Control, Mutagenesis

Journal: Disease models & mechanisms

Article Title: The Meckel-Gruber syndrome protein TMEM67 controls basal body positioning and epithelial branching morphogenesis in mice via the non-canonical Wnt pathway.

doi: 10.1242/dmm.019083

Figure Lengend Snippet: Fig. 6. Loss of Wnt5a-induced branching morphogenesis during Tmem67−/−embryonic lung ex vivo organogenesis. (A) Embryonic (E12.5) lungs were explanted and treated for 0, 6 and 24 h with either control-conditioned medium or medium containing Wnt5a. Magnified insets (black frames) under high power are shown for 24-h treatments. Epithelial branching is significantly induced by Wnt5a in Tmem67+/+ lungs, but this response is absent in Tmem67−/−lungs. The bar graph shows quantification of the total number of branches in one lung for each genotype. Values shown are means of three independent replicates and error bars indicate ±s.e.m. The statistical significance of the pair-wise comparisons are represented as *P<0.05 and n.s. for non-significant, Student’s two-tailed t-test. (B) H&E staining of ex-vivo-cultured embryonic lung sections, showing normal acini (ac) and mesenchymal tissue (ms, in green) for wild-type Tmem67+/+ lung, and the stimulation of normal epithelial branching by Wnt5a (green asterisk and arrowheads). In contrast, Tmem67−/−lungs have abnormal mesenchymal cell condensates (red arrowheads), suggesting defective epithelial-mesenchymal induction. The red asterisks indicate abnormal bronchiolar formation; cl indicates the direction of the central lung. (C) Rho activation pull-down assays of whole-cell extracts from wild-type Tmem67+/+ and mutant Tmem67−/−embryonic (E15.5) lungs. Total RhoA in input material is shown as the loading control, with the ratio indicating active:total RhoA levels. A positive control for the assay (+GTPγS; loading with non-hydrolyzable GTPγS) and a negative control (+GDP; loading with GDP) are also shown. (D) Quantitative real-time PCR assays of transcript expression levels in wild-type Tmem67+/+ and mutant Tmem67−/−embryonic (E15.5) lungs for Shh, downstream effectors of the Shh signalling pathway (Gli1 and Ptch1) and a downstream effector of the canonical Wnt signalling pathway (Axin2). Levels of transcripts were all significantly increased in Tmem67−/−embryonic lungs, with the indicated pair-wise comparisons represented as **P<0.01, Student’s two-tailed t-test for n=3 independent assays. Error bars indicate ±s.e.m.

Article Snippet: Protein expression and in vitro binding assay Purified recombinant Wnt3a and Wnt5a proteins (R&D Systems Inc.) and purified BSA as a negative control (Sigma-Aldrich Co. Ltd), were labelled with NHS-fluorescein (Thermo Fisher Scientific Inc.), as described by the manufacturer.

Techniques: Ex Vivo, Control, Two Tailed Test, Staining, Cell Culture, Activation Assay, Mutagenesis, Positive Control, Negative Control, Real-time Polymerase Chain Reaction, Expressing

Journal: Disease models & mechanisms

Article Title: The Meckel-Gruber syndrome protein TMEM67 controls basal body positioning and epithelial branching morphogenesis in mice via the non-canonical Wnt pathway.

doi: 10.1242/dmm.019083

Figure Lengend Snippet: Fig. 7. Rescue of normal embryonic lung-branching morphogenesis and polarity in mutant Tmem67−/−tissue by ex vivo treatment with the RhoA activator calpeptin. (A) Embryonic lungs (age E11.5) grown in culture for the indicated times after treatment with either vehicle control (0.1% DMSO) or calpeptin at final concentration 1 unit/ml for 3 h. Tmem67−/−lungs had abnormally dilated branches (arrowheads) surrounded by areas of condensed mesenchyme, in contrast to the fine distal branches visible in Tmem67+/+ lungs. Calpeptin treatment of mutant Tmem67−/−lungs resulted in more developed branch development and a general morphology that was similar to the wild-type lungs. Magnified insets are indicated by the black frames and shown on the right. (B) The bar graph shows the quantification of the total number of terminal branches per lung (total n=3) for each genotype and treatment condition. The statistical significance of the indicated pair-wise comparisons is *P<0.05 and **P<0.01, Student’s two-tailed t-test. Error bars indicate ±s.e.m. (C) The polarity of mitotic cell division is rescued by treatment with calpeptin from predominantly parallel (para.) in mutant alveoli to predominantly perpendicular (perp.) divisions, as observed in wild-type epithelia. The statistical significance of the indicated pair-wise comparisons is ***P<0.001, chi-squared test, with the total number of cells counted in ten fields of view indicated above each bar. Representative examples of mitotic divisions, visualised by γ-tubulin (green) and indicated by the fine dotted lines, are shown on the right. Apical surfaces are highlighted by the broad dotted lines, with asterisks indicating the alveolar lumen. Scale bar: 20 μm. (D) Schematic in which signalling through the Wnt5a-TMEM67-ROR2 axis normally represses Shh and canonical Wnt (Wnt3a) signalling to moderate levels (small green arrow) between embryonic ages E9.5 and E11.5. Loss or mutation of any component in this axis (red cross) causes loss of repression (dashed line) with Shh and canonical Wnt pathway de-regulation and ectopic expression of Shh at later gestation ages (large red arrow). This contributes to pulmonary hypoplasia with condensed mesenchyme and impaired development of the alveolar system in the ciliopathy disease state.

Article Snippet: Protein expression and in vitro binding assay Purified recombinant Wnt3a and Wnt5a proteins (R&D Systems Inc.) and purified BSA as a negative control (Sigma-Aldrich Co. Ltd), were labelled with NHS-fluorescein (Thermo Fisher Scientific Inc.), as described by the manufacturer.

Techniques: Mutagenesis, Ex Vivo, Control, Concentration Assay, Two Tailed Test, Expressing

Journal: Annals of the New York Academy of Sciences

Article Title: Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation.

doi: 10.1111/nyas.14293

Figure Lengend Snippet: Figure 1. Deletion of Wnt5a in vitro decreases osteoclast formation and function. (A) Bone marrow macrophages (BMMs) from 10-week-old male C57BL/6J (WT) or Wnt5aF/F mice were transduced with Lenti-GFP (control) or Lenti-Cre in the presence of M-CSF (30 ng/mL) and sRANKL (30 ng/mL). Lenti-Cre–mediated recombination results in excision of exon 2 of Wnt5a. (B) Wnt5aF/F BMMs transduced with Lenti-Cre had significantly lower gene expression compared with cells transduced with Lenti- GFP. (C) Wnt5aF/F BMMs transduced with Lenti-Cre had fewer osteoclasts compared with cells transduced with Lenti-GFP at day 5. No significant differences were observed in osteoclast number between Lenti-GFP– and Lenti-Cre–transduced WT BMMs. (D) Wnt5aF/F BMMs transduced with Lenti-Cre had significantly less total pit area compared with cells transduced with Lenti- GFP. No significant differences in resorbed pit area were observed between Lenti-GFP– and Lenti-Cre–transduced WT BMMs. (E) Lenti-Cre–transduced Wnt5aF/F BMMs had lower expression of the osteoclast markers Cathepsin K (Ctsk) and calcitonin receptor (Calcr) compared with Lenti-GFP–transduced Wnt5aF/F BMMs. TRAP was not significantly different. Data represent mean ± SD (n = 3), ∗P < 0.05. GFP, green fluorescent protein; WT, wild-type; OC, osteoclast.

Article Snippet: Phosphorylation was also verified by ectopic expression of full-length C-terminus Myc-DDK–tagged mouse WNT5A (Origene; Cat# MR205939) transfected into RAW 264.7 and Saos2 cells using Viromer Red (Origene; Cat# TT100302) as per the manufacturer’s protocol.

Techniques: In Vitro, Transduction, Control, Gene Expression, Expressing

Journal: Annals of the New York Academy of Sciences

Article Title: Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation.

doi: 10.1111/nyas.14293

Figure Lengend Snippet: Figure 2. Deletion of Wnt5a in mature osteoclasts does not affect osteoclast formation. (A) Wnt5a cKO mice were generated by crossing Cathepsin K-Cre mice with Wnt5aF/F mice. Cre-mediated recombination in mature osteoclasts results in excision of exon 2. (B) Representative μ-CT 3D reconstructions of femurs from 10-week-old male control and Wnt5a cKO mice. Wnt5a cKO did not influence femur length in male or female mice. (C) Wnt5a cKO resulted in a decrease in body weight in male mice but did not affect body weight in females. (D) BMMs isolated from 10-week-old male and female mice were cultured in the presence of M-CSF (25 ng/mL) alone or with sRANKL (50 ng/mL) for 5 days. Cathepsin K-Cre resulted in a significant decrease in Wnt5a gene expression from osteoclasts from both male and female mice. (E) BMMs from 10-week-old male mice were cultured in the presence of M-CSF (25 ng/mL) and sRANKL (50 ng/mL) for 3 and 5 days. The number of multinucleated osteoclasts was not significantly different between genotypes in male mice at day 3 or 5. (F) Deletion of Wnt5a resulted in a significant decrease in TRAP and calcitonin receptor gene expression at day 5 compared with controls in male and female mice. Data represent mean ± SD (n = 7–10), ∗P < 0.05. Ctsk, cathepsin K; cKO, conditional knockout; M-CSF, macrophage colony-stimulating factor; RANKL, receptor activator of nuclear factor kappa-B ligand; OC, osteoclast; Calcr, calcitonin receptor.

Article Snippet: Phosphorylation was also verified by ectopic expression of full-length C-terminus Myc-DDK–tagged mouse WNT5A (Origene; Cat# MR205939) transfected into RAW 264.7 and Saos2 cells using Viromer Red (Origene; Cat# TT100302) as per the manufacturer’s protocol.

Techniques: Generated, Control, Isolation, Cell Culture, Gene Expression, Knock-Out

Journal: Annals of the New York Academy of Sciences

Article Title: Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation.

doi: 10.1111/nyas.14293

Figure Lengend Snippet: Figure 3. Conditional deletion of Wnt5a in mature osteoclasts decreased femur microarchitectural indices without influencing osteoclast number or activity. Wnt5a cKO in 10-week-old male mice significantly decreased femoral (A) trabecular and (B) cortical microarchitectural indices. (C) Wnt5a cKO did not influence osteoclast number in vivo in femurs of 10-week-old male mice (40 × magnification). (D) No differences in serum CTX were observed in 10-week-old male mice. Data represent mean ± SD (n = 7), ∗P < 0.05. cKO, conditional knockout; BV/TV, bone volume fraction; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; BS/TV, bone surface over total volume; vBMD, volumetric bone mineral density; Ct.Th, cortical thickness; Ct.Ar, cortical area; Ct.Po, cortical porosity; N.OC/B.Pm, number of osteoclast over bone perimeter; Oc.S/BS, osteoclast surface; CTX, C-terminal telopeptide of collagen type I.

Article Snippet: Phosphorylation was also verified by ectopic expression of full-length C-terminus Myc-DDK–tagged mouse WNT5A (Origene; Cat# MR205939) transfected into RAW 264.7 and Saos2 cells using Viromer Red (Origene; Cat# TT100302) as per the manufacturer’s protocol.

Techniques: Activity Assay, In Vivo, Knock-Out

Journal: Annals of the New York Academy of Sciences

Article Title: Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation.

doi: 10.1111/nyas.14293

Figure Lengend Snippet: Figure 4. Deletion of Wnt5a from mature osteoclasts decreased bone formation. (A) Calcein double label and dynamic histomor- phometry of femoral trabecular bone from 10-week-old male Wnt5a cKO and Wnt5aF/+ control mice shows significantly lower mineralizing surface (MS/BS) and bone formation rate (BFR) when Wnt5a is deleted from mature osteoclasts. No differences in mineral apposition rates (MARs) were observed in the femur trabecular bone. (B) Deletion of Wnt5a from mature osteoclasts significantly decreased serum P1NP levels in 10-week-old male mice. Data represent mean ± SD (n = 4–7), ∗P < 0.05. cKO, conditional knockout; MS/BS, mineralizing surface; BFR, bone formation rate; MAR, mineral apposition rate; P1NP, N-terminal propeptide of type I procollagen.

Article Snippet: Phosphorylation was also verified by ectopic expression of full-length C-terminus Myc-DDK–tagged mouse WNT5A (Origene; Cat# MR205939) transfected into RAW 264.7 and Saos2 cells using Viromer Red (Origene; Cat# TT100302) as per the manufacturer’s protocol.

Techniques: Control, Knock-Out

Journal: Annals of the New York Academy of Sciences

Article Title: Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation.

doi: 10.1111/nyas.14293

Figure Lengend Snippet: Figure 5. Ctsk-Cre nonspecifically targets periosteal mesenchymal cells but does not influence osteogenic differentiation. (A) Periosteal cells (POCs) were isolated from control and experimental Wnt5a cKO mice from intact hindlimbs and subjected to osteogenic differentiation for 7, 14, and 21 days. (B) Ctsk is expressed in periosteal mesenchymal cells, with cells from Wnt5a cKO expressing 54% less. This expression resulted in significant recombination of Wnt5a in POC isolated from experimental (Wnt5a cKO) mice. (C) Expression of the osteogenic genes Runx2, Osx, and Col1a1 was not different between genotypes at day 7 or 14. At day 21 of osteogenic differentiation, POC from Wnt5a cKO mice expressed significantly higher levels of the osteogenic genes. (D) POC from Wnt5a cKO mice showed lower mineralization at day 7, but no differences in genotypes at day 14 or 21 of osteogenic differentiation. Data represent mean ± SD, ∗P < 0.05. cKO, conditional knockout; POC, periosteal cell; ARS, Alizarin red-S.

Article Snippet: Phosphorylation was also verified by ectopic expression of full-length C-terminus Myc-DDK–tagged mouse WNT5A (Origene; Cat# MR205939) transfected into RAW 264.7 and Saos2 cells using Viromer Red (Origene; Cat# TT100302) as per the manufacturer’s protocol.

Techniques: Isolation, Control, Expressing, Knock-Out

Journal: Annals of the New York Academy of Sciences

Article Title: Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation.

doi: 10.1111/nyas.14293

Figure Lengend Snippet: Figure 6. RANKL-activated RAW 264.7 cells produce a unique phosphorylated WNT5A. (A) Cellular extracts were immuno- precipitated with anti-WNT5A antibody, and then probed by immunoblotting using multiple modification-specific antibodies as indicated. Only the phospho-specific Ser antibody cross-reacted with the immunoprecipitated WNT5A in RANKL-treated RAW 264.7 cells. (B) Phosphatase (Ppase)-treated WNT5A was not detected by anti-phospho-Ser antibody, verifying it as a phosphorylation-specific modification. (C) Ectopically expressed Myc-WNT5A is inducibly phosphorylated at a Ser residue in RANKL-activated RAW 264.7 cells. (D) WNT5A is secreted into media by Saos2 and Raw 264.7 cells treated with and without RANKL. (E) Only RANKL-treated Raw 264.7 cells secrete phosphorylated WNT5A. Full length western blots are presented in Figure S4 (online only). IP, immunoprecipation; IB, immunoblot; RANKL, receptor activator of nuclear factor kappa-B ligand; Ab, antibody; Ppase, phosphatase; MmWnt5a, Mus musculus Wnt5a.

Article Snippet: Phosphorylation was also verified by ectopic expression of full-length C-terminus Myc-DDK–tagged mouse WNT5A (Origene; Cat# MR205939) transfected into RAW 264.7 and Saos2 cells using Viromer Red (Origene; Cat# TT100302) as per the manufacturer’s protocol.

Techniques: Western Blot, Modification, Immunoprecipitation, Phospho-proteomics, Residue

Journal: Molecular cell

Article Title: Paradoxical role for wild type p53 in driving therapy resistance in melanoma

doi: 10.1016/j.molcel.2019.11.009

Figure Lengend Snippet: (A) FACS analysis of slow-cycling cell populations in invasive Wnt5A high (1205Lu, FS4, FS5) and proliferative Wnt5A low (yellow bars) (FS13, FS14, FS12, WM164) melanoma cells. (ANOVA, multiple comparisons) (B) qPCR analysis of slow-cycling and cycling populations for Wnt5A mRNA. (C) FACS analysis of changes in slow-cycling cell populations following knockdown of Wnt5A using shRNA at day 3, 6, and 8 in FS5 invasive melanoma cells. (D) Western blot analysis of markers of therapy resistance, slow-cycling phenotype, and cell cycle regulation in Wnt5A high and low human melanoma cells. Active glycosylated Wnt5A is marked with arrow. β-tubulin used as a loading control. (E) Slow-cycling and cycling populations were sorted by flow cytometry and analyzed by qPCR for p53 mRNA. (F) FACS analysis of slow-cycling cells following p53 KD. (G) FACS analysis of slow-cycling cells following addition of rWnt5A to p53 knock down melanoma cells. Data are represented as mean ± SEM. (H) Expression heatmap for top genes most involved in enriched function/regulators (F,R = number of functions/regulators in which the gene is involved). * genes associated with invasion, stem cells, therapy resistance and proliferation. (I) Enriched functions activated/inhibited in WNT5A/TP53 high vs low (N- number of genes in the function. Z = activation z-score predicted by IPA). Also see Figures S1–S2.

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Wnt5A R&D systems Cat # BAF645 Jarid1B Novus Biologicals Cat # NB100-97821 p21 (human) Cell Signaling Cat # 2947S p53 Ab-6 (human) Millipore Cat # OP43 β-tubulin Cell Signaling Cat # 2146S HSP90 Cell Signaling Cat # 4877S MDM2 Calbiochem Cat # OP115-100UG MDM4(X) Abcam ab49993 iASPP Abcam ab34898 GAPDH (14C10) Cell Signaling Cat # 2118S p-MDM2ser395 Abgent AP3579a Histone H3 Cell Signaling 9715 p53 (mouse) Abcam Ab31333 Phospho-PKC α/β II (Thr638/641) Cell Signaling 9375 p21 (mouse) [ EPR18021 ] Abcam Ab188224 Bacterial and Virus Strains JM109 High Efficiency Competent Cells Promega Corp. Cat# L2001 Biological Samples Patient-derived xenografts (PDX) PFFE blocks Herlyn Lab at Wistar WM4351, WM4298, WM4070 Chemicals, Peptides, and Recombinant Proteins rWnt5A R&D 645-WN-010 PLX4720 SelleckChem S1152 PD0325901 SelleckChem S1036 G06983 Sigma G1918-500UG AIN-76A Rodent Diet Research Diets D10001i Critical Commercial Assays Qubit protein assay kit ThermoFisher cat Q33211 Duolink in situ starter kit Sigma DUO92101 Transcription Factor Fixation/Permeabilization Buffer Set Biolegend 424401 cDNA synthesis kit Bio-Rad Cat. 1708891 nuclear and cytoplasmic extraction NE-PER Fisher Product # 78833 Experimental Models: Cell Lines FS4 Webster et al. 2015 N/A FS5 Webster et al. 2015 N/A FS13 Webster et al. 2015 N/A FS14 Webster et al. 2015 N/A Yumm1.7 Meeth et al., 2016 N/A Yumm1.7 mCherry Kaur et al., 2016 N/A Yumm1.7 EmGFP This paper N/A Yumm.17 shp53_E This paper N/A 1205Lu, WM164 Rockland Immunochemicals WM793 Herlyn Lab, Wistar Institute N/A Experimental Models: Organisms/Strains C57BL6 young male mice (6–8 weeks) Charles River 556 C57BL6 young male mice (6–8 weeks) Taconic B6-M C57BL6 aged mice (43–52 weeks) retired male breeders Charles River 24107819 C57BL6 aged mice (43–52 weeks) retired male breeders Taconic B6-RB-M Oligonucleotides Primers for Wnt5A, TP53, KDM5B, PUMA, Cyclophilin A, see Table S2 This paper NA Quantum RNA Universal 18S Internal Standard ThermoFisher Cat# AM1718 Recombinant DNA pLU-EF1-MCS-mCherry This paper pLV[Exp]-Puro-EF1A>EmGFP Vector Labs Cat# VB171103-1159dvu Software and Algorithms ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/ Graphpad Prism 7 https://www.graphpad.com/data-analysis-resource-center/#guides https://www.graphpad.com/scientific-software/prism/ Open in a separate window KEY RESOURCES TABLE Wnt5A increases the half-life of wild type p53 to promote a slow cycling phenotype.

Techniques: Knockdown, shRNA, Western Blot, Control, Flow Cytometry, Expressing, Activation Assay

Journal: Molecular cell

Article Title: Paradoxical role for wild type p53 in driving therapy resistance in melanoma

doi: 10.1016/j.molcel.2019.11.009

Figure Lengend Snippet: (A) Western blot analysis of p53 expression following knockdown of Wnt5A in invasive melanoma cells with shRNA. HSP90 was used as a loading control. (B) Quantification of change in p53 half-life following shRNA knockdown of Wnt5A assessed following treatment with cycloheximide. (C) Changes in half-life of p53 upon Wnt5A knockdown. (D) Western blot of proteins known to regulate p53 expression and function in melanoma. GAPDH used as a loading control. (E) Western blot analysis of MDM2, MDM4, and p53 expression in Wnt5A high (FS4 and FS5) and low (FS13 and FS14) melanoma cells following DNA damage induced by doxorubicin (1μg/mL). HSP90 used as a loading control. (F) Western blot analysis of nuclear and cytoplasmic fractions for p-MDM2ser395, total MDM2, and p53 expression. HSP90 and Histone H3 used as loading control for cytoplasmic and nuclear fractions, respectively. (G) Proximity ligation assay for the interaction of p53 and p-MDM2ser395 in 1205Lu melanoma cells treated with rWnt5A. (H) Quantification of increased p53-pMDM2ser395 interaction in proximity ligation assay in 1205Lu and WM793 cells +/− rWnt5A (200 ng/mL). Data are represented as mean ± SEM. Also see Figure S3.

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Wnt5A R&D systems Cat # BAF645 Jarid1B Novus Biologicals Cat # NB100-97821 p21 (human) Cell Signaling Cat # 2947S p53 Ab-6 (human) Millipore Cat # OP43 β-tubulin Cell Signaling Cat # 2146S HSP90 Cell Signaling Cat # 4877S MDM2 Calbiochem Cat # OP115-100UG MDM4(X) Abcam ab49993 iASPP Abcam ab34898 GAPDH (14C10) Cell Signaling Cat # 2118S p-MDM2ser395 Abgent AP3579a Histone H3 Cell Signaling 9715 p53 (mouse) Abcam Ab31333 Phospho-PKC α/β II (Thr638/641) Cell Signaling 9375 p21 (mouse) [ EPR18021 ] Abcam Ab188224 Bacterial and Virus Strains JM109 High Efficiency Competent Cells Promega Corp. Cat# L2001 Biological Samples Patient-derived xenografts (PDX) PFFE blocks Herlyn Lab at Wistar WM4351, WM4298, WM4070 Chemicals, Peptides, and Recombinant Proteins rWnt5A R&D 645-WN-010 PLX4720 SelleckChem S1152 PD0325901 SelleckChem S1036 G06983 Sigma G1918-500UG AIN-76A Rodent Diet Research Diets D10001i Critical Commercial Assays Qubit protein assay kit ThermoFisher cat Q33211 Duolink in situ starter kit Sigma DUO92101 Transcription Factor Fixation/Permeabilization Buffer Set Biolegend 424401 cDNA synthesis kit Bio-Rad Cat. 1708891 nuclear and cytoplasmic extraction NE-PER Fisher Product # 78833 Experimental Models: Cell Lines FS4 Webster et al. 2015 N/A FS5 Webster et al. 2015 N/A FS13 Webster et al. 2015 N/A FS14 Webster et al. 2015 N/A Yumm1.7 Meeth et al., 2016 N/A Yumm1.7 mCherry Kaur et al., 2016 N/A Yumm1.7 EmGFP This paper N/A Yumm.17 shp53_E This paper N/A 1205Lu, WM164 Rockland Immunochemicals WM793 Herlyn Lab, Wistar Institute N/A Experimental Models: Organisms/Strains C57BL6 young male mice (6–8 weeks) Charles River 556 C57BL6 young male mice (6–8 weeks) Taconic B6-M C57BL6 aged mice (43–52 weeks) retired male breeders Charles River 24107819 C57BL6 aged mice (43–52 weeks) retired male breeders Taconic B6-RB-M Oligonucleotides Primers for Wnt5A, TP53, KDM5B, PUMA, Cyclophilin A, see Table S2 This paper NA Quantum RNA Universal 18S Internal Standard ThermoFisher Cat# AM1718 Recombinant DNA pLU-EF1-MCS-mCherry This paper pLV[Exp]-Puro-EF1A>EmGFP Vector Labs Cat# VB171103-1159dvu Software and Algorithms ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/ Graphpad Prism 7 https://www.graphpad.com/data-analysis-resource-center/#guides https://www.graphpad.com/scientific-software/prism/ Open in a separate window KEY RESOURCES TABLE Wnt5A increases the half-life of wild type p53 to promote a slow cycling phenotype.

Techniques: Western Blot, Expressing, Knockdown, shRNA, Control, Proximity Ligation Assay

Journal: Molecular cell

Article Title: Paradoxical role for wild type p53 in driving therapy resistance in melanoma

doi: 10.1016/j.molcel.2019.11.009

Figure Lengend Snippet: (A) Western blot analysis and quantification of basal iASPP expression in Wnt5A high (FS4 and FS5) and low (FS13 and FS14) expressing cells. (B) Western blot analysis of nuclear and cytoplasmic fractions from Wnt5A high (FS4, FS5) and Wnt5A low (FS13, FS14) melanoma cells for iASPP expression. (C) Western blot analysis of iASPP and pPKC in melanoma cells following DNA damage induced by doxorubicin (1μg/mL). (D) Quantification of apoptotic cells using AnnexinV and propidium iodide in Wnt5A high (FS4 and FS5) and Wnt5A low (FS14) cells following doxorubicin 1 ug/mL treatment. Data are represented as mean ± SEM. (E) Schematic of how Wnt5A may be activating iASPP in metastatic melanoma cells. (F) Western blot analysis of iASPP expression in melanoma cells following Wnt5A KD. Also see Figure S3.

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Wnt5A R&D systems Cat # BAF645 Jarid1B Novus Biologicals Cat # NB100-97821 p21 (human) Cell Signaling Cat # 2947S p53 Ab-6 (human) Millipore Cat # OP43 β-tubulin Cell Signaling Cat # 2146S HSP90 Cell Signaling Cat # 4877S MDM2 Calbiochem Cat # OP115-100UG MDM4(X) Abcam ab49993 iASPP Abcam ab34898 GAPDH (14C10) Cell Signaling Cat # 2118S p-MDM2ser395 Abgent AP3579a Histone H3 Cell Signaling 9715 p53 (mouse) Abcam Ab31333 Phospho-PKC α/β II (Thr638/641) Cell Signaling 9375 p21 (mouse) [ EPR18021 ] Abcam Ab188224 Bacterial and Virus Strains JM109 High Efficiency Competent Cells Promega Corp. Cat# L2001 Biological Samples Patient-derived xenografts (PDX) PFFE blocks Herlyn Lab at Wistar WM4351, WM4298, WM4070 Chemicals, Peptides, and Recombinant Proteins rWnt5A R&D 645-WN-010 PLX4720 SelleckChem S1152 PD0325901 SelleckChem S1036 G06983 Sigma G1918-500UG AIN-76A Rodent Diet Research Diets D10001i Critical Commercial Assays Qubit protein assay kit ThermoFisher cat Q33211 Duolink in situ starter kit Sigma DUO92101 Transcription Factor Fixation/Permeabilization Buffer Set Biolegend 424401 cDNA synthesis kit Bio-Rad Cat. 1708891 nuclear and cytoplasmic extraction NE-PER Fisher Product # 78833 Experimental Models: Cell Lines FS4 Webster et al. 2015 N/A FS5 Webster et al. 2015 N/A FS13 Webster et al. 2015 N/A FS14 Webster et al. 2015 N/A Yumm1.7 Meeth et al., 2016 N/A Yumm1.7 mCherry Kaur et al., 2016 N/A Yumm1.7 EmGFP This paper N/A Yumm.17 shp53_E This paper N/A 1205Lu, WM164 Rockland Immunochemicals WM793 Herlyn Lab, Wistar Institute N/A Experimental Models: Organisms/Strains C57BL6 young male mice (6–8 weeks) Charles River 556 C57BL6 young male mice (6–8 weeks) Taconic B6-M C57BL6 aged mice (43–52 weeks) retired male breeders Charles River 24107819 C57BL6 aged mice (43–52 weeks) retired male breeders Taconic B6-RB-M Oligonucleotides Primers for Wnt5A, TP53, KDM5B, PUMA, Cyclophilin A, see Table S2 This paper NA Quantum RNA Universal 18S Internal Standard ThermoFisher Cat# AM1718 Recombinant DNA pLU-EF1-MCS-mCherry This paper pLV[Exp]-Puro-EF1A>EmGFP Vector Labs Cat# VB171103-1159dvu Software and Algorithms ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/ Graphpad Prism 7 https://www.graphpad.com/data-analysis-resource-center/#guides https://www.graphpad.com/scientific-software/prism/ Open in a separate window KEY RESOURCES TABLE Wnt5A increases the half-life of wild type p53 to promote a slow cycling phenotype.

Techniques: Western Blot, Expressing

Journal: Molecular cell

Article Title: Paradoxical role for wild type p53 in driving therapy resistance in melanoma

doi: 10.1016/j.molcel.2019.11.009

Figure Lengend Snippet: (A) Flow cytometry analysis of changes in slow-cycling populations following treatment of WM35 melanoma cells with conditioned media from young (25–35 yrs) and aged (55–65 yrs) fibroblasts (two-way ANOVA sidak’s multiple comparison test). (B) Western blot analysis of Wnt5A and p53 (also see Fig. S4E) expression in Yumm1.7 derived tumors grown in young (8 wks) and aged (>52 wks) C57BL/6 mice (unpaired two-tailed t-test). (C) IHC for p53 in mouse tumors from young and aged mice for p53. (D) Quantification of p53 positive cells using ImageJ in young and aged mouse tumors. (E) Yumm1.7 cells labelled with GFP were stained with a membrane dye, PKH26, and injected into young (8 wks) and aged (>52 wks) C57BL/6 mice (2.5x105cells/mouse). (F) At week 5 post injection the tumors were analyzed for GFP+ cells that were PHK26+ by flow cytometry. (G) Flow cytometry analysis of intensity of PKH26 in GFP+ cells in tumors from young and aged tumor bearing mice. (H) Analysis of lungs from young and aged tumor bearing mice for cells that are GFP+ and PKH26+. Data are represented as mean ± SEM. Also see Figure S4.

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Wnt5A R&D systems Cat # BAF645 Jarid1B Novus Biologicals Cat # NB100-97821 p21 (human) Cell Signaling Cat # 2947S p53 Ab-6 (human) Millipore Cat # OP43 β-tubulin Cell Signaling Cat # 2146S HSP90 Cell Signaling Cat # 4877S MDM2 Calbiochem Cat # OP115-100UG MDM4(X) Abcam ab49993 iASPP Abcam ab34898 GAPDH (14C10) Cell Signaling Cat # 2118S p-MDM2ser395 Abgent AP3579a Histone H3 Cell Signaling 9715 p53 (mouse) Abcam Ab31333 Phospho-PKC α/β II (Thr638/641) Cell Signaling 9375 p21 (mouse) [ EPR18021 ] Abcam Ab188224 Bacterial and Virus Strains JM109 High Efficiency Competent Cells Promega Corp. Cat# L2001 Biological Samples Patient-derived xenografts (PDX) PFFE blocks Herlyn Lab at Wistar WM4351, WM4298, WM4070 Chemicals, Peptides, and Recombinant Proteins rWnt5A R&D 645-WN-010 PLX4720 SelleckChem S1152 PD0325901 SelleckChem S1036 G06983 Sigma G1918-500UG AIN-76A Rodent Diet Research Diets D10001i Critical Commercial Assays Qubit protein assay kit ThermoFisher cat Q33211 Duolink in situ starter kit Sigma DUO92101 Transcription Factor Fixation/Permeabilization Buffer Set Biolegend 424401 cDNA synthesis kit Bio-Rad Cat. 1708891 nuclear and cytoplasmic extraction NE-PER Fisher Product # 78833 Experimental Models: Cell Lines FS4 Webster et al. 2015 N/A FS5 Webster et al. 2015 N/A FS13 Webster et al. 2015 N/A FS14 Webster et al. 2015 N/A Yumm1.7 Meeth et al., 2016 N/A Yumm1.7 mCherry Kaur et al., 2016 N/A Yumm1.7 EmGFP This paper N/A Yumm.17 shp53_E This paper N/A 1205Lu, WM164 Rockland Immunochemicals WM793 Herlyn Lab, Wistar Institute N/A Experimental Models: Organisms/Strains C57BL6 young male mice (6–8 weeks) Charles River 556 C57BL6 young male mice (6–8 weeks) Taconic B6-M C57BL6 aged mice (43–52 weeks) retired male breeders Charles River 24107819 C57BL6 aged mice (43–52 weeks) retired male breeders Taconic B6-RB-M Oligonucleotides Primers for Wnt5A, TP53, KDM5B, PUMA, Cyclophilin A, see Table S2 This paper NA Quantum RNA Universal 18S Internal Standard ThermoFisher Cat# AM1718 Recombinant DNA pLU-EF1-MCS-mCherry This paper pLV[Exp]-Puro-EF1A>EmGFP Vector Labs Cat# VB171103-1159dvu Software and Algorithms ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/ Graphpad Prism 7 https://www.graphpad.com/data-analysis-resource-center/#guides https://www.graphpad.com/scientific-software/prism/ Open in a separate window KEY RESOURCES TABLE Wnt5A increases the half-life of wild type p53 to promote a slow cycling phenotype.

Techniques: Flow Cytometry, Comparison, Western Blot, Expressing, Derivative Assay, Two Tailed Test, Staining, Membrane, Injection

Journal: Molecular cell

Article Title: Paradoxical role for wild type p53 in driving therapy resistance in melanoma

doi: 10.1016/j.molcel.2019.11.009

Figure Lengend Snippet: (A) Tumor volume of aged (>52 wks) C57BL/6 mice injected with Yumm1.7 cells labeled with mCherry. At day 22, mice were treated with +/− PLX4720 (200mg/kg)/PD0325901(7mg/kg) and on day 23 mice were treated +/− a single intra-tumoral dose of pifithrin-α (2mg/kg). (E) IHC of p53 expression in a patient tumor pre- and post-treatment with BRAF/MEKi (Trametanib/Debrafenib). (B) Western blot analysis of p53 and p21 expression in human melanoma cells treated with 5µM pifithrin-α. (C) FACS analysis of slow cycling populations in human melanoma cell populations day 5 following treatment with 5µM pifithrin-α (one-tailed unpaired t-test analysis) (also see Fig S5C). (D) Western of Wnt5A high melanoma cell lines treated with +/− 5 μM pifithrin-α +/− 1 μg/mL doxorubicin. Quantification of changes in p53 and p21 following treatment with doxorubicin and doxorubicin combined with pifithrin-α. Data are represented as mean ± SEM. Also see Figure S5.

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Wnt5A R&D systems Cat # BAF645 Jarid1B Novus Biologicals Cat # NB100-97821 p21 (human) Cell Signaling Cat # 2947S p53 Ab-6 (human) Millipore Cat # OP43 β-tubulin Cell Signaling Cat # 2146S HSP90 Cell Signaling Cat # 4877S MDM2 Calbiochem Cat # OP115-100UG MDM4(X) Abcam ab49993 iASPP Abcam ab34898 GAPDH (14C10) Cell Signaling Cat # 2118S p-MDM2ser395 Abgent AP3579a Histone H3 Cell Signaling 9715 p53 (mouse) Abcam Ab31333 Phospho-PKC α/β II (Thr638/641) Cell Signaling 9375 p21 (mouse) [ EPR18021 ] Abcam Ab188224 Bacterial and Virus Strains JM109 High Efficiency Competent Cells Promega Corp. Cat# L2001 Biological Samples Patient-derived xenografts (PDX) PFFE blocks Herlyn Lab at Wistar WM4351, WM4298, WM4070 Chemicals, Peptides, and Recombinant Proteins rWnt5A R&D 645-WN-010 PLX4720 SelleckChem S1152 PD0325901 SelleckChem S1036 G06983 Sigma G1918-500UG AIN-76A Rodent Diet Research Diets D10001i Critical Commercial Assays Qubit protein assay kit ThermoFisher cat Q33211 Duolink in situ starter kit Sigma DUO92101 Transcription Factor Fixation/Permeabilization Buffer Set Biolegend 424401 cDNA synthesis kit Bio-Rad Cat. 1708891 nuclear and cytoplasmic extraction NE-PER Fisher Product # 78833 Experimental Models: Cell Lines FS4 Webster et al. 2015 N/A FS5 Webster et al. 2015 N/A FS13 Webster et al. 2015 N/A FS14 Webster et al. 2015 N/A Yumm1.7 Meeth et al., 2016 N/A Yumm1.7 mCherry Kaur et al., 2016 N/A Yumm1.7 EmGFP This paper N/A Yumm.17 shp53_E This paper N/A 1205Lu, WM164 Rockland Immunochemicals WM793 Herlyn Lab, Wistar Institute N/A Experimental Models: Organisms/Strains C57BL6 young male mice (6–8 weeks) Charles River 556 C57BL6 young male mice (6–8 weeks) Taconic B6-M C57BL6 aged mice (43–52 weeks) retired male breeders Charles River 24107819 C57BL6 aged mice (43–52 weeks) retired male breeders Taconic B6-RB-M Oligonucleotides Primers for Wnt5A, TP53, KDM5B, PUMA, Cyclophilin A, see Table S2 This paper NA Quantum RNA Universal 18S Internal Standard ThermoFisher Cat# AM1718 Recombinant DNA pLU-EF1-MCS-mCherry This paper pLV[Exp]-Puro-EF1A>EmGFP Vector Labs Cat# VB171103-1159dvu Software and Algorithms ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/ Graphpad Prism 7 https://www.graphpad.com/data-analysis-resource-center/#guides https://www.graphpad.com/scientific-software/prism/ Open in a separate window KEY RESOURCES TABLE Wnt5A increases the half-life of wild type p53 to promote a slow cycling phenotype.

Techniques: Injection, Labeling, Expressing, Western Blot, One-tailed Test

Journal: Molecular cell

Article Title: Paradoxical role for wild type p53 in driving therapy resistance in melanoma

doi: 10.1016/j.molcel.2019.11.009

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Wnt5A R&D systems Cat # BAF645 Jarid1B Novus Biologicals Cat # NB100-97821 p21 (human) Cell Signaling Cat # 2947S p53 Ab-6 (human) Millipore Cat # OP43 β-tubulin Cell Signaling Cat # 2146S HSP90 Cell Signaling Cat # 4877S MDM2 Calbiochem Cat # OP115-100UG MDM4(X) Abcam ab49993 iASPP Abcam ab34898 GAPDH (14C10) Cell Signaling Cat # 2118S p-MDM2ser395 Abgent AP3579a Histone H3 Cell Signaling 9715 p53 (mouse) Abcam Ab31333 Phospho-PKC α/β II (Thr638/641) Cell Signaling 9375 p21 (mouse) [ EPR18021 ] Abcam Ab188224 Bacterial and Virus Strains JM109 High Efficiency Competent Cells Promega Corp. Cat# L2001 Biological Samples Patient-derived xenografts (PDX) PFFE blocks Herlyn Lab at Wistar WM4351, WM4298, WM4070 Chemicals, Peptides, and Recombinant Proteins rWnt5A R&D 645-WN-010 PLX4720 SelleckChem S1152 PD0325901 SelleckChem S1036 G06983 Sigma G1918-500UG AIN-76A Rodent Diet Research Diets D10001i Critical Commercial Assays Qubit protein assay kit ThermoFisher cat Q33211 Duolink in situ starter kit Sigma DUO92101 Transcription Factor Fixation/Permeabilization Buffer Set Biolegend 424401 cDNA synthesis kit Bio-Rad Cat. 1708891 nuclear and cytoplasmic extraction NE-PER Fisher Product # 78833 Experimental Models: Cell Lines FS4 Webster et al. 2015 N/A FS5 Webster et al. 2015 N/A FS13 Webster et al. 2015 N/A FS14 Webster et al. 2015 N/A Yumm1.7 Meeth et al., 2016 N/A Yumm1.7 mCherry Kaur et al., 2016 N/A Yumm1.7 EmGFP This paper N/A Yumm.17 shp53_E This paper N/A 1205Lu, WM164 Rockland Immunochemicals WM793 Herlyn Lab, Wistar Institute N/A Experimental Models: Organisms/Strains C57BL6 young male mice (6–8 weeks) Charles River 556 C57BL6 young male mice (6–8 weeks) Taconic B6-M C57BL6 aged mice (43–52 weeks) retired male breeders Charles River 24107819 C57BL6 aged mice (43–52 weeks) retired male breeders Taconic B6-RB-M Oligonucleotides Primers for Wnt5A, TP53, KDM5B, PUMA, Cyclophilin A, see Table S2 This paper NA Quantum RNA Universal 18S Internal Standard ThermoFisher Cat# AM1718 Recombinant DNA pLU-EF1-MCS-mCherry This paper pLV[Exp]-Puro-EF1A>EmGFP Vector Labs Cat# VB171103-1159dvu Software and Algorithms ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/ Graphpad Prism 7 https://www.graphpad.com/data-analysis-resource-center/#guides https://www.graphpad.com/scientific-software/prism/ Open in a separate window KEY RESOURCES TABLE Wnt5A increases the half-life of wild type p53 to promote a slow cycling phenotype.

Techniques: Virus, Recombinant, Qubit Protein Assay, In Situ, Extraction, Plasmid Preparation, Software